Labiotech.eu

More News! 12 Sep 2017

Shire’s Treatment for Chronic Lung Disease in Premature Infants Fast Tracked by FDA

The FDA has fast tracked Shire’s candidate for chronic lung disease in extremely premature infants from Phase 2 of clinical development. The FDA has fast tracked Shire’s candidate, SHP607, for the treatment of chronic lung disease based on preclinical data, the results of Phase I and II studies so far, and a lack of treatments […]

September 12, 2017 - 1 minutemin - By Alex Dale

News and Trends 12 Sep 2017

Norwegian Biotech Announces Positive Phase I Results for T cell-Stimulating Vaccine

PCI Biotech’s T cell-stimulating vaccine enhances the cellular immune response, supporting it as a candidate for use alongside cancer vaccines. PCI Biotech, based in Oslo, Norway, has seen positive initial results in an ongoing Phase I trial for its firmaVacc technology. The trial is being carried out in 110 healthy subjects, and it aims to […]

September 12, 2017 - 2 minutesmins - By Alex Dale

News and Trends 12 Sep 2017

British Biotech Receives €52M Boost To Beat Antimicrobial Resistance with New Antibiotic

Summit Therapeutics has been awarded the Barda Contract worth up to $62M (€52M) to continue to the development of a new antibiotic for hospital-acquired infections. Summit Therapeutics, a biopharma company operating in the UK and US, has received the Barda Contract, designed to counter public health emergencies. In this case, the money will help to […]

September 12, 2017 - 3 minutesmins - By Alex Dale

News and Trends 12 Sep 2017

French Nanoparticle Therapy Fails to Improve Liver Cancer Treatment in Phase III

Onxeo has announced Phase III results for its nanoparticle chemotherapy Livatag, which failed to improve the outcome for patients with hepatocellular carcinoma compared to other available treatments. The stock of the French oncology specialist Onxeo was halved this morning when it revealed the results of a Phase III trial with its candidate Livatag that failed to […]

September 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Sep 2017

French Startup Raises €11M in Series A to Reinvent DNA Synthesis

DNA Script has gathered the support of key international investors to take a new, faster DNA synthesis technology closer to the market. In a Series A round led by Illumina Ventures and joined by Merck Ventures and existing investors Sofinnova Partners, Kurma Partners, and Idinvest Partners, the young French startup DNA Script has raised a total […]

September 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

imfinzi astrazeneca breakthrough designation

News and Trends 11 Sep 2017

UPDATE: AstraZeneca’s Checkpoint Inhibitor Could be a Lung Cancer Blockbuster

UPDATE: 11/09/2017: AstraZeneca has presented impressive results at ESMO that show Imfinzi adding 11 months to patient survival, or decreasing the risk of progression by 48%, in Stage 3 NSCLC. This indication represents a sizable market segment — about half of lung cancer — and Imfinzi’s first-line position could make it a blockbuster. Original Publication: […]

September 11, 2017 - 2 minutesmins - By Evelyn Warner

More News! 11 Sep 2017

Could a Protein in Yeast hold the Secret to Escaping Age-Related Diseases?

Researchers in Basel, Switzerland have identified a protein in yeast that slows protein synthesis, prolonging their lifespan. Gcn4 is a transcription factor that regulates the expression around 10% of the yeast genome. Nutrient restriction and moderate stress extend lifespan and under these conditions, yeast expresses Gcn4 to regulate protein synthesis. The aim is now to find […]

September 11, 2017 - 2 minutesmins - By Alex Dale

Gecko Biomedical Setalum surgical glue CE mark approval

News and Trends 11 Sep 2017

Gecko Biomedical’s Bio-inspired Surgical Glue Gets EU Approval

Gecko Biomedical has received CE Mark for Setalum, a light-activated biocompatible sealant, for its use in vascular reconstruction surgery. The Parisian company Gecko Biomedical has received today marketing approval in Europe for its first product; Setalum is a biocompatible polymer that can be activated on demand with light to give surgeons more control during open […]

September 11, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Interview 11 Sep 2017

Meet the CEO of Europe’s Largest & Most Fiercely Independent Biotech

Jan van de Winkel co-founded Genmab as CSO and then became CEO to develop the antibody company into a fully independent commercial enterprise. Here’s his strategy. Since its foundation in 1999, Genmab has become Europe’s largest biotech and a proud parent of a half billion-euro drug, daratumumab. Co-founding CSO Jan van de Winkel played a […]

September 11, 2017 - 8 minutesmins - By Evelyn Warner

News and Trends 9 Sep 2017

The Music of the Microbiome Questions our Identity as Humans

Slovenian artists Saša Spačal, Mirjan Švagelj and Anil Podgornik explore the meaning of human identity by letting their microbiome play music. Have you ever wondered what the microbes that live in and on you would tell you if you listened to them? A group of Slovenian artists decided to let their own microbes make music, building […]

September 9, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 Sep 2017

GSK wants in on Adaptimmune’s Adaptable T cell Cancer Treatment

GSK has backed Adaptimmune in the development of their adaptable NY-ESO SPEAR T cell cancer therapy, causing an 11% jump in their premarket value. Adaptimmune has received support from GlaxoSmithKline (GSK) for the development of their NY-ESO SPEAR T cell, which will hopefully treat a range of different cancers. The British pharma giant will pay milestones of up to £48M (€52M) […]

September 8, 2017 - 2 minutesmins - By Alex Dale

News and Trends 8 Sep 2017

Checkpoint Inhibitor from Regeneron and Sanofi gets Priority After Breakup

The FDA has granted breakthrough therapy designation to Regeneron and Sanofi for cemiplimab, just a month after announcing they will part ways soon. Cemiplimab (REGN2810) has been granted breakthrough therapy designation by the FDA for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC), considered the second deadliest skin cancer after melanoma. The antibody is a […]

September 8, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Shire’s Treatment for Chronic Lung Disease in Premature Infants Fast Tracked by FDA

Norwegian Biotech Announces Positive Phase I Results for T cell-Stimulating Vaccine

British Biotech Receives €52M Boost To Beat Antimicrobial Resistance with New Antibiotic

French Nanoparticle Therapy Fails to Improve Liver Cancer Treatment in Phase III

French Startup Raises €11M in Series A to Reinvent DNA Synthesis

UPDATE: AstraZeneca’s Checkpoint Inhibitor Could be a Lung Cancer Blockbuster

Could a Protein in Yeast hold the Secret to Escaping Age-Related Diseases?

Gecko Biomedical’s Bio-inspired Surgical Glue Gets EU Approval

Meet the CEO of Europe’s Largest & Most Fiercely Independent Biotech

The Music of the Microbiome Questions our Identity as Humans

GSK wants in on Adaptimmune’s Adaptable T cell Cancer Treatment

Checkpoint Inhibitor from Regeneron and Sanofi gets Priority After Breakup

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!